Recent headlines have once again brought high risk aesthetic procedures into focus.
The investigation into the death of mother of five Alice Webb, who became unwell following a non surgical Brazilian Butt Lift (BBL) in September 2024, was formally closed in February after the death of the primary suspect, Jordan James Parke.
While tragic cases like these have captured public attention, they also highlight a broader and long standing issue: the urgent need for clearer regulation, stronger safeguards and better public awareness across the aesthetics sector.
At the centre of this conversation are so called “high risk” procedures, including non surgical Brazilian Butt Lifts (BBLs), often performed using large volumes of dermal filler. These treatments sit at the intersection of rising consumer demand, inconsistent regulation and growing safety concerns.
Non surgical treatments have grown rapidly in popularity, driven by social media trends and the promise of quick, minimally invasive results. Procedures like liquid BBLs are often marketed as a safer alternative to surgery, but this perception can be misleading.
In reality, these treatments can involve injecting significant volumes of filler into areas of the body where products were never intended to be used. As highlighted in the Observer feature on cosmetic risk culture, the pursuit of aesthetic ideals is increasingly colliding with a lack of understanding around safety and long term outcomes.
Guidance from the Joint Council for Cosmetic Practitioners (JCCP) makes clear that dermal fillers are typically approved for facial use, not for large volume body augmentation.
As outlined in the JCCP advisory published earlier this year, dermal fillers used for procedures such as buttock or breast augmentation are often being deployed outside their intended purpose. This “off label” use introduces significant uncertainty around safety, efficacy and complication management.
The advisory states that high volume use of fillers for body augmentation cannot be supported off label and that procedures of this nature should be treated as surgical in character, requiring appropriately qualified practitioners and regulated clinical environments.
This raises serious concerns when treatments are carried out in unregulated or non clinical settings.
In addition, the Women and Equalities Committee published its Health impacts of breast implants and other cosmetic procedures report (HC 869) on 18 February 2026, calling for urgent reform of the non surgical cosmetic procedures sector, an immediate ban on liquid BBLs and stronger action on cosmetic tourism and body image pressures.
However, the concerns around BBLs are not isolated. Similar warnings have been issued regarding other high volume filler procedures.
Plastic surgeons have called for a ban on breast filler injections, citing risks including infection, tissue damage and interference with cancer detection. These procedures, like liquid BBLs, highlight a recurring issue within the sector: treatments offering limited aesthetic benefit while carrying disproportionate risk.
Recent warnings from the Joint Council for Cosmetic Practitioners (JCCP) and the British Association of Aesthetic Plastic Surgeons (BAAPS) have also highlighted wider concerns around invasive cosmetic procedures being carried out outside regulated healthcare settings.
In a joint statement issued in April, the organisations raised concerns regarding alleged unregulated surgical procedures taking place in the North West of England, including blepharoplasty, facelifts and genital surgery reportedly being performed in non clinical environments.
The organisations said procedures of this nature should only be carried out by appropriately trained medical professionals in regulated clinical settings with suitable infection control, emergency support and aftercare in place. Concerns were also raised around unclear practitioner qualifications, lack of professional registration and inadequate patient assessment.
The case has also reinforced concerns around the role of social media in promoting high risk procedures directly to consumers, often with little transparency around practitioner credentials or clinical standards.
Alongside concerns around liquid BBLs and body filler procedures, organisations including BCAM have also recently issued warnings about peptide injectables and other emerging aesthetic trends being promoted ahead of robust evidence, training or regulatory oversight.
Despite these concerns, regulation in England has historically lagged behind the pace of industry growth.
Currently, many non surgical cosmetic procedures can be performed by individuals without formal medical qualifications and outside regulated healthcare settings. This has created what many stakeholders describe as a patchwork system that leaves both patients and reputable practitioners exposed.
However, change appears to be coming. The UK Government has signalled plans to introduce tighter controls, including licensing schemes and restrictions on high risk procedures. Trading Standards has also issued warnings about the dangers of unregulated treatments, while parliamentary discussions have included proposals to ban certain high harm procedures, including liquid BBLs.
While England continues to develop its approach, Scotland has already taken decisive steps.
New legislation passed by the Scottish Parliament brings non surgical aesthetic procedures under a formal regulatory framework, recognising them as healthcare interventions rather than purely cosmetic services.
This divergence highlights a key issue. Without consistent regulation across the UK, standards and patient safety can vary significantly depending on location.
Regulation is not just about who performs treatments. It also extends to how they are marketed.
Recent findings from the Committee of Advertising Practice (CAP) revealed widespread issues in the promotion of liquid BBLs, including advertising that downplays risk, exploits body insecurities and pressures consumers into making quick decisions through limited time offers.
With only a small proportion of adverts initially meeting compliance standards, the findings point to a wider cultural issue where demand is being shaped without sufficient regard for safety.
Amid increasing demand, practitioners play a critical role in safeguarding patients.
This includes assessing suitability carefully, managing expectations realistically and refusing treatment where risks outweigh benefits.
The concept of the “power of no” is especially relevant for high risk procedures like liquid BBLs, where patient expectations may be unrealistic or heavily influenced by online trends.
The current spotlight on procedures like BBLs presents an opportunity for meaningful reform.
Clearer regulation, stronger enforcement and improved public education all have an important role to play in protecting patients, supporting responsible practitioners and restoring trust in the sector.
For a full overview of the current regulatory landscape, visit Hamilton Fraser’s Content Hub, where we have a section dedicated to regulatory updates. Find articles including:
High risk procedures such as liquid BBLs are not new, but the scale at which they are now being performed, often outside robust clinical frameworks, has intensified concerns around patient safety.
Recent events have brought these issues into sharper public focus, but the underlying challenges have been building for years. The direction of travel is increasingly clear: stronger regulation, greater accountability and higher clinical standards are likely to shape the future of the aesthetics sector.
Discover how Hamilton Fraser insurance can protect you and your practice. We cover a broad range of treatments and work closely with organisations like the JCCP. Speak to our specialist team on 0800 63 43 881 or get an online quote today.
